Form 17 – FSLP Final Evaluation in Refractory Overactive Bladder: Sacral Neuromodulation v. Botulinum Toxin Assessment

Form 17 – FSLP Final Evaluation, SAS
Study Description
The purpose of this randomized, open-label, active-control trial was to compare the effectiveness of intra-detrusor botulinum toxin A (Botox A®, Allergan) versus sacral neuromodulation (InterStim®, Medtronic) for the treatment of refractory urge urinary incontinence. In addition, the study evaluated select technical attributes of the interventions as well as the effect of these two interventions on other lower urinary tract and pelvic floor symptoms. Non-pregnant adult females at least 21 years old with refractory urinary urge incontinence

17号表格——FSLP最终评估，SAS
研究概况
本项随机、开放标签、阳性对照试验旨在比较逼尿肌内注射A型肉毒杆菌毒素（Botox A®，艾尔建（Allergan））与骶神经调控（InterStim®，美敦力（Medtronic））治疗难治性急迫性尿失禁的临床疗效。此外，本研究还评估了两种干预措施的选定技术特征，以及二者对其他下尿路及盆底症状的影响。本研究的纳入对象为年龄≥21岁的非妊娠难治性急迫性尿失禁成年女性。